STAT

Debate flares over using AI to detect Covid-19 in lung scans

The #coronavirus outbreak is providing the first opportunity for AI developers to test the feasibility of creating reliable algorithms on the fly for use in medicine.
Medical staff perform a CT scan of a Covid-19 patient at Red Cross Hospital in Wuhan, China.

A series of studies, starting as a steady drip and quickening to a deluge, has reported the same core finding amid the global spread of Covid-19: Artificial intelligence could analyze chest images to accurately detect the disease in legions of untested patients.

The results promised a ready solution to the shortage of diagnostic testing in the U.S. and some other countries and triggered splashy press releases and a cascade of hopeful headlines. But in recent days, the initial burst of optimism has given way to an intensifying debate over the plausibility of building AI systems during an unprecedented public health emergency.

On one side are AI developers and researchers who argue that training and testing methods can, and should, be modified to fit the contours of the crisis; on the other are skeptics who point to flaws in study designs and the limited number of lung scans available from coronavirus patients to train AI algorithms. They also argue that imaging should be used sparingly during the pandemic because of the risk of spreading the infection through contaminated equipment. For those and other reasons, many radiological societies have recommended against using such scans, whether supported by AI or not, for Covid-19 screening.

As AI makes increasing inroads into health care

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks